Potential novel pharmacological therapies for myocardial remodelling

Cardiovascular Research

Volumn 81, Issue 3, 2009, Pages 519-527

  Landmesser, Ulf ^a,b   Wollert, Kai C ^a   Drexler, Helmut ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Heart; Remodelling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; METOPROLOL; METOPROLOL SUCCINATE; MICRORNA; NEBIVOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PG 116800; PHOSPHODIESTERASE V INHIBITOR; ROSUVASTATIN; SILDENAFIL; SIMVASTATIN; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ADVERSE OUTCOME; ANGIOGENESIS; CELL THERAPY; CELL TRANSFER; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL STUDY; GUILLAIN BARRE SYNDROME; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; INFORMATION; ISCHEMIC HEART DISEASE; LEUKOCYTE; LEUKOCYTE ACTIVATION; NONHUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BLOCKING; REPERFUSION; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE REPAIR;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOGENESIS INDUCING AGENTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARDIOVASCULAR AGENTS; CYCLIC GMP; DRUGS, INVESTIGATIONAL; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; NITRIC OXIDE; PROTEASE INHIBITORS; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 59449108428     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn317     Document Type: Review

References (101)

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
2. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-582.
3. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005;111:2837-2849.
4. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002;106:2351-2357.
5. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004;109:1121-1126.
6. Solomon SD, Glynn RJ, Greaves S, Ajani U, Rouleau JL, Menapace F et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001;134:451-458.
7. St John Sutton M, Lee D, Rouleau JL, Goldman S, Plappert T, Braunwald E et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation 2003;107:2577-2582.
8. Yu CM, Bleeker GB, Fung JW, Schalij MJ, Zhang Q, van der Wall EE et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 2005;112:1580-1586.
9. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-1047.
10. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-1602.
11. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol 2005;95:9C-16C.
12. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319:80-86.
13. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75.
14. Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005;111:3411-3419.
15. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT et al., Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970-975.
16. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R et al., Candesartan in Heart failure Assessment of Reduction in Mortality morbidity (CHARM) Investigators Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110:2618-2626.
17. Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N, CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004;109:201-206.
18. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-1161.
19. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072-2080.
20. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-1066.
21. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003;145:292-299.
22. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997;96:2197-2205.
23. Ghio S, Magrini G, Serio A, Klersy C, Fucili A, Ronaszèki A et al., SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006;27:562-568.
24. Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS et al., REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007;116:49-56.
25. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-1697.
26. Cohn JN. Myocardial structural effects of aldosterone receptor antagonism in heart failure. J Am Coll Cardiol 2007;50:597-599.
27. Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 2007;50:591-596.
28. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429-1437.
29. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 2001;104:576-581.
30. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-985.
31. Nahrendorf M, Hu K, Hiller KH, Galuppo P, Fraccarollo D, Schweizer G et al. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. J Am Coll Cardiol 2002;40:1695-1700.
32. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-873.
33. Zacà V, Rastogi S, Imai M, Wang M, Sharov VG, Jiang A et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2007;50:551-557.
34. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001;104:1286-1291.
35. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004;110:1933-1939.
36. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-843.
37. Landmesser U, Drexler H. Chronic heart failure: an overview of conventional treatment versus novel approaches. Nat Clin Pract Cardiovasc Med 2005;2:628-638.
38. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332-337.
39. Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, proinflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007;13:1-7.
40. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-648.
41. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-254.
42. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P et al., PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:2326-2331.
43. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007;115:576-583.
44. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH et al., CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261.
45. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008 [29 August 2008, Epub ahead of print].
46. Massion PB, Balligand JL. Relevance of nitric oxide for myocardial remodeling. Curr Heart Fail Rep 2007;4:18-25.
47. Agulló L, García-Dorado D, Inserte J, Paniagua A, Pyrhonen P, Llevadot J et al. L-arginine limits myocardial cell death secondary to hypoxia-reoxygenation by a cGMP-dependent mechanism. Am J Physiol Heart Circ Physiol 1999;276:H1574-H1580.
48. Brunner F, Maier R, Andrew P, Wölkart G, Zechner R, Mayer B. Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc Res 2003;57:55-62.
49. Jones SP, Girod WG, Palazzo AJ, Granger DN, Grisham MB, Jourd'Heuil D et al. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol Heart Circ Physiol 1999;276:H1567-H1573.
50. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M et al. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2004;286:H276- H282.
51. Kanno S, Lee PC, Zhang Y, Ho C, Griffith BP, Shears LL 2nd et al. Attenuation of myocardial ischemia/reperfusion injury by super-induction of inducible nitric oxide synthase. Circulation 2000;101: 2742-2748.
52. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 2003;93:907-916.
53. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schrosuperder F et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 2002;99:11363-11368.
54. Heineke J, Kempf T, Kraft T, Hilfiker A, Morawietz H, Scheubel RJ et al. Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy. Circulation 2003;107:1424- 1432.
55. Wegener JW, Nawrath H, Wolfsgruber W, Kühbandner S, Werner C, Hofmann F et al. cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ Res 2002;90:18-20.
56. Wollert KC, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E et al. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 2002;39:87-92.
57. Fiedler B, Feil R, Hofmann F, Willenbockel C, Drexler H, Smolenski A et al. cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes. J Biol Chem 2006;281:32831-32840.
58. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-222.
59. Sorrentino SA, Doerries C, Mohmand W, Akbar R, Besler C, Schaefer A et al. Effect of nebivolol vs. metoprolol on endothelial function, endothelial progenitor cell mobilization and left ventricular remodeling and dysfunction early after myocardial infarction. Circulation 2006;114:370 (abstract).
60. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008;118:818-827.
61. Sam F, Sawyer DB, Xie Z, Chang DL, Ngoy S, Brenner DA et al. Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res 2001;89:351-356.
62. Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 2007;100:1089-1098.
63. Gilson WD, Epstein FH, Yang Z, Xu Y, Prasad KM, Toufektsian MC et al. Borderzone contractile dysfunction is transiently attenuated and left ventricular structural remodeling is markedly reduced following reperfused myocardial infarction in inducible nitric oxide synthase knockout mice. J Am Coll Cardiol 2007;50:1799-1807.
64. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002;109:735-743.
65. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007;100:894-903.
66. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Müller M et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 2004;110:2175-2179.
67. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:241-248.
68. Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Pérez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 2006;12:491-498.
69. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS et al., OPT-CHF Investigators Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008;51:2301-2309.
70. Vasilyev N, Williams T, Brennan ML, Unzek S, Zhou X, Heinecke JW et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 2005;112:2812-2820.
71. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003;197:615-624.
72. Brown EJ Jr, Kloner RA, Schoen FJ, Hammerman H, Hale S, Braunwald E. Scar thinning due to ibuprofen administration after experimental myocardial infarction. Am J Cardiol 1983;51:877-883.
73. Hammerman H, Kloner RA, Schoen FJ, Brown EJ Jr, Hale S, Braunwald E. Indomethacin-induced scar thinning after experimental myocardial infarction. Circulation 1983;67:1290-1295.
74. Timmers L, Sluijter JP, Verlaan CW, Steendijk P, Cramer MJ, Emons M et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007;115:326-332.
75. Straino S, Salloum FN, Baldi A, Ockaili RA, Piro M, Das A et al. Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol 2007;50:571-577.
76. Fang L, Gao XM, Moore XL, Kiriazis H, Su Y, Ming Z et al. Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J Mol Cell Cardiol 2007;43:535-544.
77. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;108:2905-2910.
78. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 2008;102:257-264.
79. Riad A, Jäger S, Sobirey M, Escher F, Yaulema-Riss A, Westermann D et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol 2008;180:6954-6961.
80. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S et al. Anakinra a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008;117:2670-2683.
81. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008;117:2662-2669.
82. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98:351-360.
83. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1054-1060.
84. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;115:962-971.
85. Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 2007;116:1540-1548.
86. Mirotsou M, Zhang Z, Deb A, Zhang L, Gnecchi M, Noiseux N et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci USA 2007;104:1643-1648.
87. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002;90:520-530.
88. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008 [8 July 2008, Epub ahead of print].
89. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002;105:753-758.
90. Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006;48:15-20.
91. Yarbrough WM, Mukherjee R, Escobar GP, Mingoia JT, Sample JA, Hendrick JW et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 2003;108:1753-1759.
92. Spinale FG, Escobar GP, Hendrick JW, Clark LL, Camens SS, Mingoia JP et al. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther 2006;318:966-973.
93. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007;28:711-718.
94. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-2118.
95. Heineke J, Auger-Messier M, Xu J, Oka T, Sargent MA, York A et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest 2007;117:3198-3210.
96. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y et al. p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007;446:444-448.
97. Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 2003;107:461-468.
98. Yoon YS, Wecker A, Heyd L, Park JS, Tkebuchava T, Kusano K et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 2005;115:326-338.
99. Zeng L, Hu Q, Wang X, Mansoor A, Lee J, Feygin J et al. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 2007;115:1866-1875.
100. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104:1046-1052.
101. Wollert KC. Cell therapy for acute myocardial infarction. Curr Opin Pharmacol 2008;8:202-210.